Esperion Therapeutics | ESPR - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Cipla INR 6.14B 3.63B 2026-03
CSL USD 2.64B 1.97B 2025-12
Cytokinetics USD -181.23M 2.86M 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Geron USD -236K 10.55M 2026-03
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sanofi EUR 1.94B 239M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12